Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab FDC SC vs IV in Previously Untreated Advanced Melanoma
NCT05625399Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of nivolumab and relatlimab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days, Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05625399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625399.